drugset / Trial / NCT02119819
A Study to Compare a New Drug for Type 2 Diabetes to Placebo and to a Treatment Already Available for Type 2 Diabetes
RandomizedParallel-groupDouble-blindTreatment
Summary
The main purpose of this study is to compare the safety and effectiveness of the study drug known as LY2944876 to exenatide extended-release and placebo in participants with type 2 diabetes mellitus. All drugs will be given by an injection under the skin. Participants remain on stable doses of metformin, as prescribed by their personal investigator if they were on metformin at study entry. Participants' involvement in the study is expected to last about 30 weeks.
Timeline
- Start
- 2014-04
- Primary completion
- 2015-08
- Completion
- 2015-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Exenatide | Peptide | 2 mg | Subcutaneous |
| Subject | PEGAPAMODUTIDE | Protein / enzyme biologic | 10 mg | Subcutaneous |
| Subject | PEGAPAMODUTIDE | Protein / enzyme biologic | 15 mg | Subcutaneous |
| Subject | PEGAPAMODUTIDE | Protein / enzyme biologic | 30 mg | Subcutaneous |
| Subject | PEGAPAMODUTIDE | Protein / enzyme biologic | 50 mg | Subcutaneous |
| Background | Metformin | Small molecule | — | Oral |